Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
about
The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseasesPharmacology of anabolic steroidsThe effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young menAndrogens and prostate diseaseAdverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic ReviewEvidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasiaOxidative stress in prostate hyperplasia and carcinogenesisControlled release of dutasteride from biodegradable microspheres: in vitro and in vivo studiesRedesigning a large-scale clinical trial in response to negative external trial results: the CAMUS study of phytotherapy for benign prostatic hyperplasia.Testosterone and erectile function: from basic research to a new clinical paradigm for managing men with androgen insufficiency and erectile dysfunction.Simultaneous pharmacokinetic and pharmacodynamic analysis of 5α-reductase inhibitors and androgens by liquid chromatography tandem mass spectrometryCurrent status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH.Recent Advances in Drug Design and Drug Discovery for Androgen- Dependent Diseases.Hormonal therapy in female pattern hair loss.Analysis of testosterone and dihydrotestosterone in mouse tissues by liquid chromatography-electrospray ionization-tandem mass spectrometry.Variation in AKR1C3, which encodes the neuroactive steroid synthetic enzyme 3α-HSD type 2 (17β-HSD type 5), moderates the subjective effects of alcoholDihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer.Role of 5α-reductase inhibitors in benign prostatic diseases.Dutasteride reduces alcohol's sedative effects in men in a human laboratory setting and reduces drinking in the natural environmentEffects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation.Safety and tolerability of DIM-based therapy designed as personalized approach to reverse prostatic intraepithelial neoplasia (PIN).5α-reductase type 1 modulates insulin sensitivity in men.Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy.Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy.Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice GuidelineOral testosterone with and without concomitant inhibition of 5α-reductase by dutasteride in hypogonadal men for 28 days.Neurosteroids are endogenous neuroprotectants in an ex vivo glaucoma model.5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.Molecular Basis of Steroid Action in the Prostate.Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis.Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability.Pilot Study of 15 Patients Receiving a New Treatment Regimen for Androgenic Alopecia: The Effects of Atopy on AGA.Dutasteride: an evidence-based review of its clinical impact in the treatment of benign prostatic hyperplasia.Identification of the patient with enlarged prostate: diagnosis and guidelines for management.Agents in development for prostate cancer prevention.Epidemiology of prostate cancer and treatment remarks.Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.Anti-proliferative activities of finasteride in benign prostate epithelial cells require stromal fibroblasts and c-Jun geneAndrogen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer.Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer?
P2860
Q21285041-DC33389E-44BD-468F-8C67-52BF59917C1BQ24650695-42155507-4D55-4ACC-9115-3BA8E84CA551Q24658075-8943BEA1-857B-4EA1-B2A6-FB4A66E22ACCQ27010093-09298090-EDEA-4349-81F8-01164545C337Q28069186-09ABA076-122D-4A58-BF96-C04401B9D992Q28077954-5F34EFE3-0250-4A93-9438-7C30B8A4C387Q28079474-42616390-5338-43A8-BF47-A0816CE1C923Q28542853-A144B3B5-14EA-4A27-99CE-992F7C7E5C45Q30432603-3C971FA7-87CF-454C-BD08-5EC0F3112CC1Q33276072-D060928A-DA0E-4673-8AB9-13C73C84DE1DQ33463058-67CFB6D4-ECE2-4316-AA5E-1B2C4BEEF9BEQ33602452-F2F51B7A-F8A4-4C3D-8158-D3829EC1D397Q33623428-F823A006-5DFA-46DB-9957-09DB753C33C3Q33641738-948C6F75-A27B-4E99-8D8A-F32D9CC89012Q33875919-7437D7AF-865E-42D5-9FF5-DCCAA9D1178CQ34054066-B126EDAD-7F84-4EBC-BEBB-81AA25BEF885Q34204078-4847ACFF-F1F5-442E-ADD3-AC7769978BBCQ34254296-672724E5-BCAD-4042-906F-18BC3AFC626EQ34273786-F74657E2-4B1C-4738-96FE-21F5EA9758DDQ34313221-2EC5E6EA-FE41-40D6-AF01-B782440AA7EFQ34323757-64769296-84B1-409A-BE28-FB9A729A4803Q34396472-209F75D8-F138-4F7C-9ACF-9556969BDB3EQ34497901-D5087F21-6B14-4797-A7CA-D4B8F620C80FQ34528225-1C09194A-CC4E-441B-B2B1-4AFE31453AEEQ34604979-A11A1691-A37B-4C8A-8DBA-4AD0ED78CD68Q34710289-E5191DC4-D687-4897-B816-A3A0B8C643A3Q34789708-77A47115-F24E-4B93-B212-C4D20FFD2EF1Q34887797-35497E56-5DB1-4959-81B8-712F32C9E0E2Q35024939-D022C01C-5505-44A9-8900-DC0FD0B19D5CQ35087049-E894BCDD-528C-4D66-9080-8B30C6685A33Q35328005-6AEE13C0-3D2E-4DF9-8931-241D75925EE8Q35684314-2009E4EB-0CC3-4F78-B111-BF383D8D858EQ35876383-98CE704E-69D4-4268-9929-8DA0900DACB0Q35945368-FB473C4D-B701-40E1-8F6C-B6EB50046557Q35964705-9D97B7B9-A9D3-4743-B54B-D1A26ADB70DCQ36081918-6D375B1D-5AE3-475A-9C29-A39C6286C1EBQ36118714-580C82E4-131B-460C-8DF3-00539DAABCCBQ36280003-EA673E64-12FA-40C0-A905-AA48657CC80AQ36298863-6CF25E31-FF0C-45EC-A619-D09E0A050223Q36303823-1C85F4B2-E2DD-47F3-9759-121C3ECF87D5
P2860
Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
description
2004 nî lūn-bûn
@nan
2004 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Marked suppression of dihydrot ...... al 5alpha-reductase inhibitor.
@ast
Marked suppression of dihydrot ...... al 5alpha-reductase inhibitor.
@en
Marked suppression of dihydrot ...... al 5alpha-reductase inhibitor.
@nl
type
label
Marked suppression of dihydrot ...... al 5alpha-reductase inhibitor.
@ast
Marked suppression of dihydrot ...... al 5alpha-reductase inhibitor.
@en
Marked suppression of dihydrot ...... al 5alpha-reductase inhibitor.
@nl
prefLabel
Marked suppression of dihydrot ...... al 5alpha-reductase inhibitor.
@ast
Marked suppression of dihydrot ...... al 5alpha-reductase inhibitor.
@en
Marked suppression of dihydrot ...... al 5alpha-reductase inhibitor.
@nl
P2093
P356
P1476
Marked suppression of dihydrot ...... al 5alpha-reductase inhibitor.
@en
P2093
Betsy B Morrill
David J Hermann
Glenn R Cunningham
Richard V Clark
Stuart Hobbs
Timothy H Wilson
P304
P356
10.1210/JC.2003-030330
P407
P577
2004-05-01T00:00:00Z